[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602013":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":16,"armGroups":13,"interventions":13,"overallOfficials":13,"centralContacts":17,"locations":23,"responsibleParty":140,"collaborators":13,"id":142,"slug":13,"hasResults":143,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":143,"sex":149,"minAge":150,"maxAge":13,"enrollmentInfo":151,"targetDuration":13,"studyType":154,"phases":13,"briefSummary":155,"conditions":156,"keywords":13,"overallStatus":25,"whyStopped":13,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},{"fullName":5,"class":6},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Response to second-line basedow treatment","Practices in France regarding the use of these second-line treatments appear to be heterogeneous, and their effectiveness has never been compared through randomized studies.\n\ninvestigators propose to collect and analyze the therapeutic outcomes of second-line treatment in patients with Graves' orbitopathy. The data collection concerns patients with Graves' orbitopathy who have received corticosteroid therapy and a second-line treatment (immunosuppressant, biotherapy) since 2022.\n\nData from the medical records of patients included.","Patients who started a second-line treatment between January 2022 and December 2023, with clinical follow-up until the end of 2024, were included in order to minimize selection bias. inclusion period: until december 2025",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":6,"timePerspective":15,"maskingInfo":13},"RETROSPECTIVE","The data collection concerns patients with Graves' orbitopathy who have received corticosteroid treatment and second-line treatment (immunosuppressants, biotherapy) since 2015, 2021, or 2022. A decision was made to limit the inclusion to patients who started second-line treatment between January 2022 and December 2023, with clinical follow-up until the end of 2024, in order to limit selection bias and ensure an adequate follow-up period.\n\nThe inclusion period extends until June 2025.",[18],{"name":19,"role":20,"phone":21,"phoneExt":13,"email":22},"Boris BIENVENU, DR","CONTACT","0140021738","bbienvenu@15-20.fr",[24,39,52,65,78,91,104,114,127],{"facility":5,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Paris","paris","75012","France","FR",{"type":32,"coordinates":33},"Point",[34,35],2.3488,48.85341,{"lat":35,"lon":34},[38],{"name":19,"role":20,"phone":13,"phoneExt":13,"email":13},{"facility":40,"status":25,"city":41,"state":13,"zip":42,"country":29,"countryCode":30,"cosmosGeoPoint":43,"geoPoint":47,"contacts":48},"CHU Caen Normandie COTE DE NACRE","Caen","14000",{"type":32,"coordinates":44},[45,46],-0.35912,49.18585,{"lat":46,"lon":45},[49],{"name":50,"role":20,"phone":13,"phoneExt":13,"email":51},"Jean Claude QUINTYN, DR","quintyn-jc@chu-caen.fr",{"facility":53,"status":25,"city":54,"state":13,"zip":55,"country":29,"countryCode":30,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"CHU Lyon - Hospices Civils de Lyon","Lyon","69002",{"type":32,"coordinates":57},[58,59],4.84789,45.74906,{"lat":59,"lon":58},[62],{"name":63,"role":20,"phone":13,"phoneExt":13,"email":64},"Juliette ABEILLON, DR","juliette.abeillon@chu-lyon.fr",{"facility":66,"status":25,"city":67,"state":13,"zip":68,"country":29,"countryCode":30,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Hopital Saint Joseph","Marseille","13285",{"type":32,"coordinates":70},[71,72],5.38107,43.29695,{"lat":72,"lon":71},[75],{"name":76,"role":20,"phone":13,"phoneExt":13,"email":77},"Antoine POULER, DR","apoulet@hopital-saint-joseph.fr",{"facility":79,"status":25,"city":80,"state":13,"zip":81,"country":29,"countryCode":30,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"CHU de Montpellier","Montpellier","34295",{"type":32,"coordinates":83},[84,85],3.87635,43.61093,{"lat":85,"lon":84},[88],{"name":89,"role":20,"phone":13,"phoneExt":13,"email":90},"Yves-Marie PERS, PR","ym-pers@chu-montpellier.fr",{"facility":92,"status":25,"city":93,"state":13,"zip":94,"country":29,"countryCode":30,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"CHU Nîmes","Nîmes","30900",{"type":32,"coordinates":96},[97,98],4.35788,43.83665,{"lat":98,"lon":97},[101],{"name":102,"role":20,"phone":13,"phoneExt":13,"email":103},"Olivier GOHIER, DR","OLIVIER.GILLY@chu-nimes.fr",{"facility":105,"status":25,"city":26,"state":13,"zip":106,"country":29,"countryCode":30,"cosmosGeoPoint":107,"geoPoint":109,"contacts":110},"Hopital Fondation de Rothschild","75019",{"type":32,"coordinates":108},[34,35],{"lat":35,"lon":34},[111],{"name":112,"role":20,"phone":13,"phoneExt":13,"email":113},"Clara BOUCHE, DR","cbouche@for.paris",{"facility":115,"status":25,"city":116,"state":13,"zip":117,"country":29,"countryCode":30,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"CHU de Pontchaillou","Rennes","35000",{"type":32,"coordinates":119},[120,121],-1.67431,48.11109,{"lat":121,"lon":120},[124],{"name":125,"role":20,"phone":13,"phoneExt":13,"email":126},"Na'im BEN MILOUD, DR","Naim.BEN.MILOUD@chu-rennes.fr",{"facility":128,"status":25,"city":129,"state":13,"zip":130,"country":29,"countryCode":30,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Hopital Civil \u002F Nouvel Hopital Civil","Strasbourg","67000",{"type":32,"coordinates":132},[133,134],7.74553,48.58392,{"lat":134,"lon":133},[137],{"name":138,"role":20,"phone":13,"phoneExt":13,"email":139},"Lauriana SOLECKI, DR","lauriana.solecki@chru-strasbourg.fr",{"type":141,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100602013",false,"NCT07117981","Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment","Treatment of Graves' Orbitopathy in Patients Failing Corticosteroid Therapy: Multicenter National Retrospective Study- Basedow","HZN-IIT","Inclusion Criteria:\n\n* Patients aged 18 and older with moderate to severe orbitopathy;\n* Patients followed in endocrinology with the goal of achieving euthyroidism;\n* Corticosteroid-resistant patients: patients who have received at least 3 weeks of treatment with 500 mg weekly corticosteroid boluses and have not shown improvement in the clinical activity score (CAS);\n* Corticosteroid-dependent patients: relapse with a CAS of 3 or higher when decreasing or stopping corticosteroid therapy;\n* Patients with a CAS ≥ 3 or CAS \\\u003C3 with moderate to severe orbitopathy (according to EUGOGO);\n* Patients treated with immunotherapy, biotherapy, or radiotherapy as second-line treatment;\n* Patients who are not opposed to the reuse of their health data.\n\nExclusion Criteria:\n\n* Patients who have undergone bone or fat decompression surgery;\n* Patients with severe corneal involvement (Grade B or C; NO SPECS classification);\n* Patients with optic neuropathy (Grade B and C; NO SPECS classification);\n* Patients who have received 1 gram corticosteroid boluses for dysthyroid orbitopathy;\n* Patients who have opposed the reuse of their health data.","ALL","18 Years",{"count":152,"type":153},100,"ESTIMATED","OBSERVATIONAL","Describe the progression of inflammatory orbitopathy and the biological progression of patients receiving second-line treatment (immunosuppressants, radiotherapy, or biotherapy).",[157],"Basedow Disease","2025-08-12",{"date":160,"type":161},"2025-08-15","ACTUAL",{"date":163,"type":161},"2024-11-01",{"date":165,"type":153},"2025-12",{"name":5,"class":6},9]